Articles tagged with Cell Therapies
Cancer cells secrete type III collagen to stay dormant, and when levels decrease, they wake up and create metastatic cancer. Researchers found that enriching the environment with collagen can force cells to remain in a dormant state and prevent tumor recurrence.
A case study published in Nature Medicine reports a patient experiencing progressive neurological features resembling Parkinson's disease after CAR-T cell therapy, suggesting potential neurotoxicity. The study highlights the importance of monitoring for neurotoxicity in patients receiving BCMA-targeted CAR-T therapies.
IN8bio is developing a genetically modified gamma-delta T cell technology to treat glioblastoma multiforme. Preclinical studies published in Scientific Reports show significant improvement in survival outcomes, and a Phase I clinical trial is underway at UAB.
Researchers at A*STAR's Institute of Molecular and Cell Biology have discovered a novel protein therapy using Agrin to promote wound healing and repair. The study found that timely induction or exogenous supplementation of Agrin accelerates the healing process, preserving the mechanical architecture of injured skin layers.
Researchers create a porous microneedle to deliver CAR T cells into solid tumors, improving anti-tumor effects. The strategy showed enhanced tumor infiltration and amplification of CAR T cells in melanoma models.
A team of researchers has developed a Dynamic Sampling Platform to analyze cells in real-time, overcoming the time-consuming and expensive process of biomanufacturing. The platform provides insight into cell behavior and biochemical information needed for process control, potentially lowering the cost of cell therapies.
Researchers used next-generation DNA sequencing to detect residual disease in patients treated with CAR-T therapy for acute lymphoblastic leukemia. The study found that DNA sequencing was more sensitive and accurate than flow cytometry in predicting relapse, enabling earlier intervention.
Recent clinical trials showed promising results with cardiosphere-derived cells, improving heart parameters in patients with Duchenne muscular dystrophy. Researchers investigate using cell-derived products like exosomes to boost endogenous repair pathways, while aiming to reverse cardiomyocytes' proliferation limitations.
Researchers have developed an assay that uses specific immune-biomarkers to monitor patient survival chances and effectiveness of ovarian cancer treatments. The 'sFIS' assay will enable targeted therapy for each patient, improving treatment outcomes.
Researchers at Children's National Hospital have successfully developed a personalized T cell immunotherapy that targets and kills unique proteins in individual tumor cells. This approach, combining genetic sequencing and protein identification, offers a promising treatment option for children with hard-to-treat brain tumors.
A fasting-mimicking diet was found to be safe and biologically active in cancer patients, with potential benefits for modulation of metabolism and enhancement of antitumor immunity. The study demonstrated significant reductions in blood glucose and growth factor concentrations, as well as enhancements in intratumor T-cell infiltration.
A new study led by University of Minnesota Medical School researcher Xavier Revelo found that macrophages play a role in protecting the heart after injury. The research team discovered a large increase in cardiac macrophages early in response to a cardiac injury similar to high blood pressure.
New study suggests inhibiting Shp2 in tumor cells may boost tumor growth and survival, complicating its use as a potential cancer therapy for HCC.
Researchers are developing a transformative technology called Multiscale Intelligent Convergence (MusIC) to map the complexity of T cells and identify attributes essential for patient benefit. The goal is to create more reliable biomanufacturing of T cell infusion products and engineering potent immune cells.
Researchers found that certain T cells stop working before entering the tumor due to changes in gene expression, making ICB therapies less effective. Combining ICB with other forms of immunotherapy targeting different aspects of T cell function may improve response rates for non-small cell lung cancer patients.
Researchers have discovered a potential new treatment for COVID-19 by targeting the pentose phosphate pathway, which is necessary for SARS-CoV-2 replication. The study found that inhibiting this pathway with benfooxythiamine suppresses viral replication and reduces virus production.
Researchers at MIT and Harvard University have developed a way to selectively turn on gene therapies in target cells by detecting specific messenger RNA sequences. This technology can fine-tune gene therapies for applications ranging from regenerative medicine to cancer treatment, potentially reducing side effects and increasing efficacy.
A new, bacteria-based system can detect cancer cells and release therapeutic drugs directly into them, leaving healthy cells intact. The technology has shown promising results in preclinical tests on mice, particularly for liver cancer.
Researchers have developed nanoparticles that can communicate with and slow the development of cancer cells. The nanoparticles aggregate in cancer cells, reducing metabolic activity and growth, and are activated by MMP-9 enzyme secreted by cancer cells.
Researchers discovered that leukemia cells immediately unresponsive to treatment have high levels of SAMHD1, while those with acquired resistance use the enzyme DCK to activate nucleoside analogues. This finding may lead to better cancer therapies.
Researchers developed a new protein treatment that prevents glaucoma from forming in mice and reduces pressure in the eyes. The study provides new targets for therapies and aims to develop an injectable treatment for patients.
A recent study highlights the negative effects of misinformation on stem cell therapies for COVID-19, including exaggerated claims and unregulated sales. The researchers advocate for increased enforcement of laws and regulations to protect patients and promote responsible science communication.
Researchers found that optimizing energy metabolism through autophagy can improve the immune system response in HIV-affected cells, providing a potential therapeutic approach. This metabolic optimization enables CD4 lymphocytes to better defend against HIV-1 by secreting IL-21, a key protein in defense against the virus.
A new pouch device has been developed to protect transplanted human liver cells from immune systems for up to six months, producing crucial biomolecules. This breakthrough offers a potential path toward treating human diseases without needing to suppress the patient's immune system.
A phase Ib study found that combining sotorasib, a KRAS G12C inhibitor, with afatinib, a pan-ErbB tyrosine kinase inhibitor, showed antitumor activity in patients with KRAS-mutant non-small cell lung cancer. The combination demonstrated a high disease control rate and improved efficacy compared to prior therapies.
Researchers found that CAR-T cells require a high number of antigens to kill melanoma cells, but TCR-T cells are more effective in detecting and killing tumor cells with lower levels of target molecules. This study could lead to better immunotherapies for solid tumors.
Researchers have developed a new cancer photodrug that can treat deep-seated tumors more effectively and with reduced toxicity. Copper cysteamine photosensitizers allow the production of reactive oxygen species to kill cancer cells, minimizing damage to healthy cells.
Researchers comprehensively review T-cell responses to respiratory viral infections and chronic obstructive pulmonary disease (COPD), highlighting key characteristics of peptide-reactive T-cells. The review aims to improve understanding of the underlying mechanisms, leading to more effective immune protection and treatment methods.
A new study provides evidence supporting the involvement of aquaporins in corneal cell proliferation and nerve regeneration, suggesting AQP5 induction as a potential therapy to accelerate corneal defect resurfacing. The study found that AQP5 deficiency can slow down corneal epithelial repair, but its specific mechanism remained unclear.
Researchers at Mount Sinai have developed a novel therapy called MS67 that effectively fights acute myeloid leukemia with mixed lineage leukemia rearrangement. The therapy degrades the WDR5 protein, which drives the proliferation of this type of leukemia and other cancers such as pancreatic cancer.
Researchers have developed a novel immunotherapy approach using PBMCs to generate TEM/TCM cells for adoptive cell therapy in multiple myeloma. The treatment targets WT1-specific cytotoxic T lymphocytes, which show high sensitivity to MM cells, providing a promising basis for an additional therapeutic strategy.
New targeted therapies are being developed to target genetic alterations in cancer cells, such as the ARID1A mutation found in 10-50% of solid tumours. Early clinical trials suggest that these agents may be effective in treating multiple cancers, including breast, ovarian, and gastric cancer.
Researchers discovered that new mutations in the BRAF gene can lead to gliomas growing back after treatment, suggesting personalized approaches to therapy. The study also explored potential impacts of COVID-19 vaccines on menstruation.
A study by MedUni Wien researchers has discovered that the transcription factor BATF3 and its target genes play a crucial role in the growth of tumour cells in anaplastic large cell lymphoma. The findings suggest that targeting the IL-2R system could be an effective therapeutic approach, with promising results in animal models.
A team of researchers from IOCB Prague has discovered a new type of nanoparticles capable of safely transporting various types of nucleic acids used for therapeutic purposes into cells. The universal nature of their system sets it apart from existing solutions, allowing for efficient transport of mRNA and other RNA molecules into cells.
Scientists at City of Hope and Griffith University developed a novel anti-HIV protein called ZPAMt that can suppress HIV levels in the bone marrow, spleen, and brain of mice. The protein is delivered using exosomes, nanosized parts of cells that can reach difficult-to-access areas of the body.
A new trial run by UCL researchers shows promise in slowing the regrowth of tumors among some bowel cancer patients. The drug adavosertib was found to delay tumour growth by about two months on average and had relatively few side effects, particularly in left-sided/rectal tumours.
A recent study found that amniotic fluid-derived, neonatal, and adult cells can be used to deliver long-lasting Factor VIII protein for Hemophilia A treatment. The researchers identified cells from umbilical cord tissue as the most promising candidates, which yielded high levels of Factor VIII mRNA and blood clotting activity.
Researchers at MD Anderson Cancer Center presented new findings on novel therapeutic approaches, including cell therapy for solid tumors and antibody drug conjugates targeting TROP2. The therapies achieved partial responses in six patients, with an overall response rate of 35.3% and disease control rate of 70.6%.
Researchers at the University of Birmingham discovered that T cells send messages from five specific genes in their immune response to drugs given to treat skin cancer. This finding suggests that an optimal level of stimulation is required for a strong immune response, and blocking certain immune brakes may re-awaken dormant T cells.
Researchers develop a novel cell reprogramming strategy to transform glioma cells into non-proliferative neurons. This approach shows promise in slowing down the growth of GBMs and overcoming harmful side effects of conventional treatments.
Researchers at Max-Planck-Gesellschaft engineered synthetic exosomes that regulate cellular signaling during wound closure, leading to faster healing and improved formation of new blood vessels. The study provides a systematic understanding of extracellular vesicle communication and its potential therapeutic application.
Researchers developed lab-grown cochlear organoids to screen FDA-approved drugs for hair cell-inducing properties. The study identified Regorafenib as a potent stimulator of hair cell formation, even regenerating lost cells in mouse tissues.
Researchers have created a new technology to enhance therapeutic antibodies' ability to attack blood cancer cells by leveraging the human immune system. This approach combines IgM and IgG antibodies, resulting in a single molecule with increased complement activation.
Researchers at Thomas Jefferson University have discovered a drug cocktail that can mitigate disc degeneration associated with aging, reducing chronic back pain. By targeting senescent cells, the treatment slowed disc degeneration when administered early in life.
Researchers found that early life irradiation-induced γH2AX foci persisted in adult mice, leading to brain aging and shortened lifespan. The study suggests a potential link between early life radiation exposure and later-stage neurodegenerative disorders.
Isaac Hilton is using non-integrating episomal DNA viruses to create a new platform technology for cell and gene therapies. He aims to hijack these viruses to safely program medicinal functions in human cells.
The HIPGEN study, a multinational trial, investigates the efficacy and safety of allogeneic placenta-expanded adherent stromal cells to improve recovery after hip fracture arthroplasty. The trial aims to combat immobility and associated problems by strengthening periarticular hip musculature.
A CRISPR screening tool identified ZMYND8, an epigenetic regulatory protein, as a potential new therapeutic target for acute myeloid leukemia. Inhibiting ZMYND8 has been shown to leave cancer cells with smaller tumors and better survival in mouse models.
Patients with relapsed metastatic melanoma who received prior anti-PD-1 therapies had a lower response rate to adoptive cell transfer of tumor-infiltrating lymphocytes (ACT-TIL). ACT-TIL was less effective in these patients compared to those who had never received anti-PD-1 therapy. The study found that the objective response rate and ...
A study conducted at a Brazilian university found that treatment with curcumin and light reduces parasite load and eliminates Leishmania parasites completely. Curcumin showed good distribution in macrophages and reduced amastigotes' viability, changing their mitochondrial activity.
Researchers have developed heat-controllable CAR T cells that can target and destroy cancerous tumors, while preventing relapse. The cells are engineered to produce immunomodulators under photothermal control, increasing their effectiveness against solid tumors.
Researchers at the University of Pennsylvania School of Medicine have identified a new mechanism of resistance in advanced chronic lymphocytic leukemia (CLL) patients to CAR T cell therapy. They found that inhibiting the BET protein with the small molecule inhibitor JQ1 can reinvigorate exhausted T cells and increase their production.
Researchers at UC San Diego developed a cancer immunotherapy that pairs ultrasound with CAR T-cell therapy to destroy malignant tumors while sparing normal tissue. The therapy significantly slowed down tumor growth in mice and showed minimal on-target, off-tumor side effects.
A new process for making RNA has been developed by researchers at the University of Massachusetts Amherst, yielding purer and more abundant RNA at a fraction of the cost. This breakthrough removes the largest stumbling block on the path to next-generation RNA therapeutic drugs.
A comprehensive molecular map of lung squamous cell carcinoma has identified potential new drug targets, including the gene NSD3, and highlighted immune regulation pathways that could help cancer evade immunotherapies. The study's findings have also revealed metabolic dysregulation and crosstalk between different cellular processes.
Researchers identified molecular markers to purify unstable regulatory T cells, which can switch from protective to damaging function. Exposing these cells to a destabilizing environment also removes the unstable cells, leaving behind stable regulatory T cells for therapeutic use.
Researchers at Mayo Clinic Cancer Center are studying a potential new chimeric antigen receptor-T cell therapy (CAR-T cell therapy) treatment for multiple myeloma. The overall response rate to the treatment was 97%, while the complete response rate and progression-free survival rates were 67% and 77%, respectively.
Researchers at Trinity College Dublin and ONK Therapeutics are collaborating to optimize the metabolism of natural killer cells for enhanced anti-tumor functions. The project aims to address the immunosuppressive tumor microenvironment that impairs NK cell efficacy.
Researchers developed RADICA, a molecular rapid testing methodology for detecting viral nucleic acids in 40-60 minutes. The method has been tested on SARS-CoV-2 synthetic DNA/RNA and Epstein-Barr virus and shows high sensitivity and specificity.